Laura Mendez

Iterion initiates Phase 1 clinical trial to investigate tegavivint in a first-line combination study with osimertinib in previously untreated patients with metastatic epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer.

Children’s Oncology Group Pediatric Early Phase Clinical Trials Network, a National Cancer Institute-supported clinical trials group, sponsors first clinical study for tegavivint in the pediatric population

Iterion Therapeutics announces phase 1 clinical trial.

Iterion Therapeutics hires Jean Chang as Chief Operating Officer.  

Iterion Therapeutics confirms safety of tegavivint following completion of enrollment in phase 1/2a expansion study.

Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings.